Epclusa (Sofosbuvir/Velpatasvir) Patent Expiration, LOE Window & CMS Spending

Epclusa (Sofosbuvir/Velpatasvir) by Gilead Sciences: FDA Orange Book core substance LOE 2033-05-16 (last listed 2034-07-30), 0 AB generics, $852.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGilead Sciences
FDA Application & PathwayN208341 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2033-05-16
Last Listed Patent or Exclusivity Date2034-07-30
Orange Book Patents (*PED Extensions)30 patents (15 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$852.1M
2024 Medicare Part D Spend$758.0M
2024 Medicaid Spend$94.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.